Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation
AssigneeThomas Jefferson University
InventorsJoel Rosenbloom, Edward John Macarak
Life of this patent
Estimating the term…
Abstract
A method of reducing the severity of abdominal adhesion due to surgical complications comprising: administering to said patient at least a first dose of trametinib between 0.01 mg to 2.0 mg, and after said surgical procedure, administering to said patient a further dose of trametinib between 0.01 mg to 2.0 mg, daily, for at least seven days post-surgery.
Claims3
A method of reducing the occurrence of excessive fibrin formation in a patient consisting of administering to said patient one effective dose of Trametinib (GSK1120212) sufficient to reduce the fibrin formation prior to a surgical procedure, and a further dose of the Trametinib (GSK1120212) for seven days after said surgical procedure daily, wherein the effective dose of Trametinib (GSK1120212) is between 0.01 mg to 1.5 mg.
Dependencies are inferred from the claim text.